Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Steven M Devine

Showing results (131-140 of 178) with videos related to

Pageof 18
Sort By:
Blood Advances|October 6, 2025
Matched unrelated vs haploidentical donor hematopoietic cell transplantation using posttransplant cyclophosphamideDipenkumar Modi, Yosra M Aljawai, Todd E DeFor, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 17, 2024
Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis Attenuates Disparity in Outcomes Between Use of Matched or Mismatched Unrelated DonorsBrian C Shaffer, Mahasweta Gooptu, Todd E DeFor, et al.
Journal for Immunotherapy of Cancer|August 25, 2021
Early toxicity and clinical outcomes after chimeric antigen receptor T-cell (CAR-T) therapy for lymphomaJonathan E Brammer, Zachary Braunstein, Aashish Katapadi, et al.
Blood|May 9, 2012
Clinical and pharmacodynamic activity of bortezomib and decitabine in acute myeloid leukemiaWilliam Blum, Sebastian Schwind, Somayeh S Tarighat, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 6, 2017
Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic SyndromesBart L Scott, Marcelo C Pasquini, Brent R Logan, et al.
JAMA|March 7, 2023
DNA Sequencing to Detect Residual Disease in Adults With Acute Myeloid Leukemia Prior to Hematopoietic Cell TransplantLaura W Dillon, Gege Gui, Kristin M Page, et al.
Bone Marrow Transplantation|October 18, 2024
Measurable residual FLT3 tyrosine kinase domain mutations before allogeneic transplant for acute myeloid leukemiaPranay S Hegde, Georgia Andrew, Gege Gui, et al.
Bone Marrow Transplantation|April 10, 2022
Impact of COVID-19 pandemic on global unrelated stem cell donations in 2020-Report from World Marrow Donor AssociationMonique M Jöris, Alexander H Schmidt, Stefanie N Bernas, et al.
Medrxiv : the Preprint Server for Health Sciences|August 14, 2023
Measurable Residual <i>IDH1</i> before Allogeneic Transplant for Acute Myeloid LeukemiaGege Gui, Laura W Dillon, Niveditha Ravindra, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 21, 2019
Impact of Conditioning Intensity of Allogeneic Transplantation for Acute Myeloid Leukemia With Genomic Evidence of Residual DiseaseChristopher S Hourigan, Laura W Dillon, Gege Gui, et al.
Pageof 18

Showing results (131-140 of 178) with videos related to

Sort By:
Pageof 18
Blood Advances|October 6, 2025
Matched unrelated vs haploidentical donor hematopoietic cell transplantation using posttransplant cyclophosphamideDipenkumar Modi, Yosra M Aljawai, Todd E DeFor, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 17, 2024
Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis Attenuates Disparity in Outcomes Between Use of Matched or Mismatched Unrelated DonorsBrian C Shaffer, Mahasweta Gooptu, Todd E DeFor, et al.
Journal for Immunotherapy of Cancer|August 25, 2021
Early toxicity and clinical outcomes after chimeric antigen receptor T-cell (CAR-T) therapy for lymphomaJonathan E Brammer, Zachary Braunstein, Aashish Katapadi, et al.
Blood|May 9, 2012
Clinical and pharmacodynamic activity of bortezomib and decitabine in acute myeloid leukemiaWilliam Blum, Sebastian Schwind, Somayeh S Tarighat, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 6, 2017
Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic SyndromesBart L Scott, Marcelo C Pasquini, Brent R Logan, et al.
JAMA|March 7, 2023
DNA Sequencing to Detect Residual Disease in Adults With Acute Myeloid Leukemia Prior to Hematopoietic Cell TransplantLaura W Dillon, Gege Gui, Kristin M Page, et al.
Bone Marrow Transplantation|October 18, 2024
Measurable residual FLT3 tyrosine kinase domain mutations before allogeneic transplant for acute myeloid leukemiaPranay S Hegde, Georgia Andrew, Gege Gui, et al.
Bone Marrow Transplantation|April 10, 2022
Impact of COVID-19 pandemic on global unrelated stem cell donations in 2020-Report from World Marrow Donor AssociationMonique M Jöris, Alexander H Schmidt, Stefanie N Bernas, et al.
Medrxiv : the Preprint Server for Health Sciences|August 14, 2023
Measurable Residual <i>IDH1</i> before Allogeneic Transplant for Acute Myeloid LeukemiaGege Gui, Laura W Dillon, Niveditha Ravindra, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 21, 2019
Impact of Conditioning Intensity of Allogeneic Transplantation for Acute Myeloid Leukemia With Genomic Evidence of Residual DiseaseChristopher S Hourigan, Laura W Dillon, Gege Gui, et al.
Pageof 18